全文获取类型
收费全文 | 3499篇 |
免费 | 275篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 155篇 |
妇产科学 | 78篇 |
基础医学 | 538篇 |
口腔科学 | 31篇 |
临床医学 | 260篇 |
内科学 | 824篇 |
皮肤病学 | 120篇 |
神经病学 | 540篇 |
特种医学 | 89篇 |
外科学 | 229篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 203篇 |
眼科学 | 33篇 |
药学 | 266篇 |
中国医学 | 9篇 |
肿瘤学 | 402篇 |
出版年
2024年 | 5篇 |
2023年 | 37篇 |
2022年 | 73篇 |
2021年 | 130篇 |
2020年 | 94篇 |
2019年 | 114篇 |
2018年 | 122篇 |
2017年 | 100篇 |
2016年 | 124篇 |
2015年 | 144篇 |
2014年 | 162篇 |
2013年 | 204篇 |
2012年 | 278篇 |
2011年 | 282篇 |
2010年 | 178篇 |
2009年 | 139篇 |
2008年 | 250篇 |
2007年 | 243篇 |
2006年 | 243篇 |
2005年 | 225篇 |
2004年 | 178篇 |
2003年 | 174篇 |
2002年 | 139篇 |
2001年 | 18篇 |
2000年 | 12篇 |
1999年 | 18篇 |
1998年 | 23篇 |
1997年 | 18篇 |
1996年 | 14篇 |
1995年 | 7篇 |
1994年 | 7篇 |
1993年 | 11篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1976年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
1911年 | 1篇 |
1905年 | 1篇 |
排序方式: 共有3803条查询结果,搜索用时 15 毫秒
931.
Lucilla Parnetti Valeria Caso Alessia Lanari Emanuele Saggese Michela Sebastianelli Seyed Khosrow Tayebati 《Clinical and experimental hypertension (New York, N.Y. : 1993)》2013,35(3-4):335-344
Randomized trials with statins have shown a modest but significant absolute reduction in the incidence of stroke in patients with a previous myocardial infarction. The reasons for the positive statin effect on stroke endpoint are unclear, because a link between serum cholesterol level and stroke never has been established. However, positive results of statin trials were mainly obtained in patients with an average or a low serum cholesterol level. Statins have a good overall safety profile. Statins reduced stroke incidence in high-risk (mainly coronary heart disease, diabetics, and hypertensives) population even with a normal baseline blood cholesterol level.In patients with prior strokes, statins reduce the incidence of coronary events, but it is not yet proven if drugs of this class actually reduce the incidence of recurrent strokes in terms of secondary prevention. 相似文献
932.
933.
Valeria Cento Formijn Van Hemert Maria Neumann-Fraune Carmen Mirabelli Velia-Chiara Di Maio Romina Salpini Ada Bertoli Valeria Micheli Guido Gubertini Sara Romano Michela Visca Giuseppe-Maria De Sanctis Ben Berkhout Nicoletta Marino Francesco Mazzotta Giuseppina Cappiello Alberto Spanò Cesare Sarrecchia Francesca Ceccherini-Silberstein Massimo Andreoni Mario Angelico Jens Verheyen Carlo Federico Perno Valentina Svicher 《The Journal of infection》2013
934.
Maria Lucia Narducci Gemma Pelargonio Eleonora Russo Leonardo Marinaccio Antonio Di Monaco Francesco Perna Gianluigi Bencardino Michela Casella Luigi Di Biase Pasquale Santangeli Rosalinda Palmieri Christian Lauria Ghaliah Al Mohani Francesca Di Clemente Claudio Tondo Faustino Pennestri Carolina Ierardi Antonio G. Rebuzzi Filippo Crea Fulvio Bellocci Andrea Natale Antonio Dello Russo 《Journal of the American College of Cardiology》2013
935.
Gian Paolo Fadini Natalino Simioni Vera Frison Michela Dal Pos Michela Bettio Paola Rocchini Angelo Avogaro 《Acta diabetologica》2013,50(6):943-949
The GLP-1 receptor agonist Liraglutide is effective in reducing HbA1c in type 2 diabetic (T2D) patients. In addition, treatment with Liraglutide is associated with significant weight loss. In this study, we analyzed the inter-relationships between glycemic and weight effects of Liraglutide treatment in a population of type 2 diabetic outpatients. T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up. We collected baseline information about anthropometric data, cardiovascular risk factors, diabetes duration, prevalence of complications and history of anti-diabetic medications. We collected HbA1c and body weight at baseline and every 4 months. A total of 166 patients were included, who were on average 56.6 ± 8.9 (mean ± SD) years old and had a baseline HbA1c of 8.7 ± 1.3 % and BMI 36.3 ± 6.4 kg/m2. Mean follow-up was 9.4 ± 4.2 months (range 4–16). Patients lost on average 1.5 ± 1.3 % HbA1c and 4.0 ± 5.0 kg body weight. Most patients (73.5 %) improved HbA1c and loosed weight. Significant independent determinants of HbA1c drop were baseline HbA1c (r = 0.673; p < 0.001) and previous insulin therapy (r = ?0.251; p < 0.001). The only independent determinant of weight loss was baseline BMI (r = 0.429; p < 0.001). Drop in HbA1c was unrelated to baseline BMI or weight loss. Weight loss was unrelated to baseline HbA1c or drop in HbA1c. Glycemic improvement and weight reduction obtained with Liraglutide treatment in T2D patients in a real-world setting are independent and possibly mediated by different mechanisms. 相似文献
936.
Chiara Castellani Giorgio Vescovo Barbara Ravara Chiara Franzin Michela Pozzobon Regina Tavano Luisa Gorza Emanuele Papini Roberto Vettor Paolo De Coppi Gaetano Thiene Annalisa Angelini 《International journal of cardiology》2013
Background
The aim of our study was to investigate whether stem cell (SC) therapy with human amniotic fluid stem cells (hAFS, fetal stem cells) and rat adipose tissue stromal vascular fraction cells–GFP positive cells (rSVC-GFP) was able to produce favorable effects on skeletal muscle (SM) remodeling in a well-established rat model of right heart failure (RHF).Methods
RHF was induced by monocrotaline (MCT) in Sprague–Dawley rats. Three weeks later, four millions of hAFS or rSVC-GFP cells were injected via tail vein. SM remodeling was assessed by Soleus muscle fiber cross sectional area (CSA), myocyte apoptosis, myosin heavy chain (MHC) composition, satellite cells pattern, and SC immunohistochemistry.Results
hAFS and rSVC-GFP injection produced significant SC homing in Soleus (0.68 ± 1.0 and 0.67 ± 0.75% respectively), with a 50% differentiation toward smooth muscle and endothelial cells. Pro-inflammatory cytokines were down regulated to levels similar to those of controls.SC-treated (SCT) rats showed increased CSA (p < 0.004 vs MCT) similarly to controls with a reshift toward the slow MHC1 isoform. Apoptosis was significantly decreased (11.12. ± 8.8 cells/mm3 hAFS and 13.1 + 7.6 rSVC-GFP) (p < 0.001 vs MCT) and similar to controls (5.38 ± 3.0 cells/mm3).RHF rats showed a dramatic reduction of satellite cells(MCT 0.2 ± 0.06% Pax7 native vs controls 2.60 ± 2.46%, p < 0.001), while SCT induced a repopulation of both native and SC derived satellite cells (p < 0.005).Conclusions
SC treatment led to SM remodeling with satellite cell repopulation, decreased atrophy and apoptosis. Modulation of the cytokine milieu might play a crucial pathophysiological role with a possible scenario for autologous transplantation of SC in pts with CHF myopathy. 相似文献937.
Luca Ciprian Alessandro Lo Nigro Michela Rizzo Alessandra Gava Roberta Ramonda Leonardo Punzi Franco Cozzi 《Rheumatology international》2013,33(1):241-245
Despite advances in pharmacological therapy, physical treatment continues to be important in the management of ankylosing spondylitis (AS). The objective of the present study was to evaluate the effects and tolerability of combined spa therapy and rehabilitation in a group of AS patients being treated with TNF inhibitors. Thirty AS patients attending the Rheumatology Unit of the University of Padova being treated with TNF inhibitors for at least 3 months were randomized and assessed by an investigator independent from the spa staff: 15 were prescribed 10 sessions of spa therapy (mud packs and thermal baths) and rehabilitation (exercises in a thermal pool) and the other 15 were considered controls. The patients in both groups had been receiving anti-TNF agents for at least three months. The outcome measures utilized were BASFI, BASDAI, BASMI, VAS for back pain and HAQ. The evaluations were performed in all patients at the entry to the study, at the end of the spa treatment, and after 3 and 6 months. Most of the evaluation indices were significantly improved at the end of the spa treatment, as well as at the 3 and 6 months follow-up assessments. No significant alterations in the evaluation indices were found in the control group. Combined spa therapy and rehabilitation caused a clear, long-term clinical improvement in AS patients being treated with TNF inhibitors. Thermal treatment was found to be well tolerated and none of the patients had disease relapse. 相似文献
938.
Paolo Verdecchia Maria Cristina Vedovati Serenella Conti Michela Giustozzi Adolfo Aita Gabriella Molini 《Expert opinion on drug safety》2013,12(11):1063-1069
ABSTRACTIntroduction: Most studies on thromboembolic and bleeding risk in patients with non-valvular atrial fibrillation (NVAF) exposed to non-vitamin K oral anticoagulants stem from interrogation of insurance databases.Areas covered: We studied 742 consecutive patients with NVAF who started treatment with dabigatran in three hospitals in Italy. Average follow-up was 1.80 years.Mean age was 76.2 years. CHA2DS2VASc score was 0–1 in 37 (5%), 2 in 97 (13%) and ≥ 3 in 604 (82%) patients. NVAF was permanent in 349 (48%). Overall, 76% of patients remained on treatment over the entire follow-up period. Among 180 patients who discontinued permanently, the most frequent reasons were dyspepsia (33.9%), bleeding (17.8%), and renal worsening (12.1%). About 48% and 74% of permanent discontinuations occurred during the first 6 and 12 months of treatment, respectively. Rates of major events (per 100 patient-years) were 0.75 for stroke, 0.31 for myocardial infarction, 1.50 for all-cause death, and 1.80 for major bleedings. The rate of intracranial bleedings was 0.45 and that of major gastrointestinal bleedings was 0.75.Expert opinion: This prospective cohort study confirms the low incidence of stroke, major bleeding and intracranial bleeding, and a 76% persistence with treatment, in patients with NVAF treated with dabigatran over about 2 years. 相似文献
939.
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia 总被引:7,自引:0,他引:7
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
940.
De Coppi P Callegari A Chiavegato A Gasparotto L Piccoli M Taiani J Pozzobon M Boldrin L Okabe M Cozzi E Atala A Gamba P Sartore S 《The Journal of urology》2007,177(1):369-376
PURPOSE: Wound healing of the cryo-injured bladder can bring about organ remodeling because of incomplete reconstitution of depleted smooth muscle cells. Stem cell transplantation could be beneficial to improve smooth muscle cell regeneration and/or modulate the remodeling process. The repair of bladder injury using adult-type stem cells would be useful for adult urological patients but unsuited for neonatal patients, in whom major benefits are likely to derive from fetal-type stem cells. MATERIALS AND METHODS: The smooth muscle cell differentiation potential of fetal-type vs adult-type stem cells was evaluated by injecting green fluorescent protein labeled mesenchymal stem cells from rat amniotic fluid or bone marrow, respectively, in cryo-injured rat bladder walls. RESULTS: At 30 days after transplantation only a few fetal-type or adult-type mesenchymal stem cells gave rise to enteric or vascular smooth muscle cells, whereas most mesenchymal stem cells appeared incapable of specific differentiation. In vitro co-culture experiments of smooth muscle cells with fetal-type or adult-type mesenchymal stem cells selectively labeled with distinct fluorochromes showed the presence of hybrid cells, suggesting that some mesenchymal stem cells can undergo cell fusion. Surprisingly the major effect of rat bone marrow or amniotic fluid mesenchymal stem cell transplantation seemed to be preventing cryo-injury induced hypertrophy of surviving smooth muscle cells. CONCLUSIONS: In this model stem cell transplantation has a limited effect on smooth muscle cell regeneration. Instead it can regulate post-injury bladder remodeling, possibly via a paracrine mechanism. 相似文献